Last reviewed · How we verify
Pegylated Interferon-alpha2a
Pegylated Interferon-alpha2a is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved. Also known as: Pegasys.
Pegylated Interferon-alpha2a is a protein-based therapeutic agent used to treat various conditions, including chronic hepatitis B and C, and chronic myeloid leukemia. It is available in different dosages, including 24 mcg, 48 mcg, and 90 mcg, as indicated by ClinicalTrials.gov.
At a glance
| Generic name | Pegylated Interferon-alpha2a |
|---|---|
| Also known as | Pegasys |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
- Effect of Storytelling on Questionnaire Completion and Quality of Collected Data in an E-Cohort (NA)
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) (PHASE3)
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated Interferon-alpha2a CI brief — competitive landscape report
- Pegylated Interferon-alpha2a updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI
Frequently asked questions about Pegylated Interferon-alpha2a
What is Pegylated Interferon-alpha2a?
Who makes Pegylated Interferon-alpha2a?
Is Pegylated Interferon-alpha2a also known as anything else?
What development phase is Pegylated Interferon-alpha2a in?
Related
- Manufacturer: Seoul National University Hospital — full pipeline
- Also known as: Pegasys
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing